PAPER Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M, Huntington Study Group SIGNAL investigators

Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.

Nat Med. 2022 Oct;28(10):2183-2193. Epub 2022 Aug 8 PubMed. Correction.

Yan Xiuying

Sarah Elsea

Baylor College of Medicine
United States

John Shadle

The University of Wisconsin-Madison
United States

Philip Wardley

Australia

Loni Ajagbe

Jiwon Park

, Korea, Republic of

Holly Korthas

University of Minnesota
United States

Dominique Leitner

New York University

Ben Rabichow

Mayo Clinic
United States

Miguel Robles-Varela

Mexico

Linh Tran

Worsak Kanok

Chulalongkorn University
Thailand

Halford Greenlee

Yolande Pijnenburg

Amsterdam UMC
Netherlands